Date: 2016-02-03
Type of information: Nomination
Compound: chief executive officer
Company: Maxivax (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 3, 2016, MaxiVAX, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced the appointment of Dimitrios Goundis Ph.D., as its Chief Executive Officer. He joins the company after holding several senior management and R & D positions at The Medicines Company, Speedel and Roche, both in Europe and the US.
- Dimitrios was awarded his PhD in Biochemistry from the University of Oxford, a BSc (Hons) in Chemistry and Biochemistry from the University of London, and a certificate in investment management from the London Business School.
Financial terms:
Latest news:
Is general: Yes
